Dr. Inoshi Atukorale
Multi-center Randomised, Double-Blind, Placebo-controlled 76 week study to evaluate the efficary and safety of Belimumab, a fully human monoclonal Anti BLys antibody in subjects with Systemic Lupus Erythematosis
Phase III, Multi-center Randomised, Double-Blind, Placebo-controlled 76 week study to evaluate the efficary and safety of Belimumab, a fully human monoclonal Anti BLys antibody in subjects with Systemic Lupus Erythematosis, recruiting
Leave a Reply